Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system - PubMed (original) (raw)
Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system
Robert D Bell et al. J Cereb Blood Flow Metab. 2007 May.
Abstract
Amyloid beta-peptide (Abeta) clearance from the central nervous system (CNS) maintains its low levels in brain. In Alzheimer's disease, Abeta accumulates in brain possibly because of its faulty CNS clearance and a deficient efflux across the blood-brain barrier (BBB). By using human-specific enzyme-linked immunosorbent assays, we measured a rapid 30 mins efflux at the BBB and transport via the interstitial fluid (ISF) bulk flow of human-unlabeled Abeta and of Abeta transport proteins, apolipoprotein E (apoE) and apoJ in mice. We show (i) Abeta40 is cleared rapidly across the BBB via low-density lipoprotein receptor-related protein (LRP)1 at a rate of 0.21 pmol/min g ISF or 6-fold faster than via the ISF flow; (ii) Abeta42 is removed across the BBB at a rate 1.9-fold slower compared with Abeta40; (iii) apoE, lipid-poor isoform 3, is cleared slowly via the ISF flow and across the BBB (0.03-0.04 pmol/min g ISF), and after lipidation its transport at the BBB becomes barely detectable within 30 mins; (iv) apoJ is eliminated rapidly across the BBB (0.16 pmol/min g ISF) via LRP2. Clearance rates of unlabeled and corresponding 125I-labeled Abeta and apolipoproteins were almost identical, but could not be measured at low physiologic levels by mass spectrometry. Amyloid beta-peptide 40 binding to apoE3 reduced its efflux rate at the BBB by 5.7-fold, whereas Abeta42 binding to apoJ enhanced Abeta42 BBB clearance rate by 83%. Thus, Abeta, apoE, and apoJ are cleared from brain by different transport pathways, and apoE and apoJ may critically modify Abeta clearance at the BBB.
Figures
Fig. 1
a, SDS-PAGE analysis of crude extract of human plasma apoJ. b, HPLC purification of the crude apoJ extract. c, SDS-PAGE analysis of the apoJ peak in b (reduced conditions). ApoAI, apolipoprotein A one.
Fig. 2
a, Time-disappearance curves of unlabeled human Aβ40 (0.0866 ng) and 14C-inulin from brain ISF after their simultaneous administration into the caudate nucleus in mice. Each pair of time points represents data from individual mice for Aβ and inulin. b, Clearance of unlabeled human synthetic Aβ40 and Aβ42 from brain ISF within 30 min of administration into the caudate nucleus. Aβ40 and Aβ42 were infused simultaneously with 14C-inulin. c, Levels of Aβ40 in brain after 30 min of its simultaneous administration with inulin (not shown) in the presence and absence of anti-LRP1 (N-20, 60 μg/mL), non-immune IgG (60 μg/mL) and RAP (5 μM). d, Intact human unlabeled Aβ40 and Aβ42 in plasma 30 min after local CNS administration of peptides simultaneously with 14C-inulin in the presence and absence of centrally administered anti-LRP1 (N-20, 60 μg/mL). Inulin levels were barely detectable (not shown). Aβ levels were determined focally in brain and plasma by using human specific ELISAs, as described in Methods. In b-d, values are mean ± s.e.m. from 3 to 5 independent experiments.
Fig. 3
a, Clearance of unlabeled human apoE (isoform 3; 0.70 ng), non-lipidated and lipidated, from brain ISF within 30 min of administration into the caudate nucleus. ApoE was infused simultaneously with 14C-inulin. b, Clearance of native human apoJ (1.6 ng) from brain ISF within 30 min of its simultaneous administration into the caudate nucleus with 14C-inulin. c, Clearance of unlabeled Aβ40 and apoE (isoform 3) administered into brain ISF simultaneously with 14C-inulin either alone (closed bars) or in the form of Aβ- apoE complex (open bars). Inulin values not shown. ApoE, apoJ and Aβ levels were determined focally in brain and plasma by using human specific ELISAs, as described in Methods. Values are mean ± s.e.m. from 3 to 5 independent experiments.
Fig. 4
a, Brain clearance of unlabeled (solid bars) and 125I-labeled (open bars) Aβ and apolipoproteins from brain ISF. The same amounts of unlabeled and the respective 125I-labeled Aβ40, Aβ42, apoE non-lipidated and lipidated isoform 3 and apoJ were infused with 14C-inulin into brain ISF in the caudate nucleus. The levels of unlabeled Aβ and apoE were determined by human specific ELISAs (solid bars) and of 125I-labeled Aβ and apoE by gamma counting (open bars). The percentage recovery was calculated as Nt/N0 × 100 (eq. 1, Methods). Mean ± s.e.m., n = 3-8. b, Clearance of 125I-apoJ (1.6 ng/0.5 μL; TCA-precipitable radioactivity) in the absence and presence of RAP (5 μM), anti-LRP-2 (Rb 6286, 60 μg/ml, from Dr. S. Argraves ) and anti-LRP-1 (N20, 60 μg/ml) simultaneously infused with 14C-inulin. c, Effects of apoJ on 125I-Aβ42 clearance from brain ISF and effect of anti-LRP2 (Rb 6286, 60 μg/ml ). For b-c, values are mean ± s.e.m., n = 3-5.
Similar articles
- Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.
Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV. Ma Q, et al. Mol Neurodegener. 2018 Oct 19;13(1):57. doi: 10.1186/s13024-018-0286-0. Mol Neurodegener. 2018. PMID: 30340601 Free PMC article. - Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of Aβ.
Miners JS, Clarke P, Love S. Miners JS, et al. Brain Pathol. 2017 May;27(3):305-313. doi: 10.1111/bpa.12392. Epub 2016 Jul 8. Brain Pathol. 2017. PMID: 27248362 Free PMC article. - Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
Shackleton B, Crawford F, Bachmeier C. Shackleton B, et al. Fluids Barriers CNS. 2016 Aug 8;13(1):14. doi: 10.1186/s12987-016-0038-x. Fluids Barriers CNS. 2016. PMID: 27503326 Free PMC article. - Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E.
Fan J, Donkin J, Wellington C. Fan J, et al. Biofactors. 2009 May-Jun;35(3):239-48. doi: 10.1002/biof.37. Biofactors. 2009. PMID: 19472365 Review.
Cited by
- Astrocyte-derived clusterin disrupts glial physiology to obstruct remyelination in mouse models of demyelinating diseases.
Chen C, Shu Y, Yan C, Li H, Huang Z, Shen S, Liu C, Jiang Y, Huang S, Wang Z, Mei F, Qin F, Liu X, Qiu W. Chen C, et al. Nat Commun. 2024 Sep 6;15(1):7791. doi: 10.1038/s41467-024-52142-7. Nat Commun. 2024. PMID: 39242637 Free PMC article. - Trajectory of brain-derived amyloid beta in Alzheimer's disease: where is it coming from and where is it going?
Liu N, Haziyihan A, Zhao W, Chen Y, Chao H. Liu N, et al. Transl Neurodegener. 2024 Aug 19;13(1):42. doi: 10.1186/s40035-024-00434-9. Transl Neurodegener. 2024. PMID: 39160618 Free PMC article. Review. - Mathematical modelling of Alzheimer's disease biomarkers: Targeting Amyloid beta, Tau protein, Apolipoprotein E and Apoptotic pathways.
Patel H, Solanki N, Solanki A, Patel M, Patel S, Shah U. Patel H, et al. Am J Transl Res. 2024 Jul 15;16(7):2777-2792. doi: 10.62347/UJQF5204. eCollection 2024. Am J Transl Res. 2024. PMID: 39114703 Free PMC article. Review. - Low-Density Lipoprotein Receptor-Related Protein 1 as a Potential Therapeutic Target in Alzheimer's Disease.
Petralla S, Panayotova M, Franchina E, Fricker G, Puris E. Petralla S, et al. Pharmaceutics. 2024 Jul 17;16(7):948. doi: 10.3390/pharmaceutics16070948. Pharmaceutics. 2024. PMID: 39065645 Free PMC article. Review. - Cellular and molecular mechanisms of the blood-brain barrier dysfunction in neurodegenerative diseases.
Chen T, Dai Y, Hu C, Lin Z, Wang S, Yang J, Zeng L, Li S, Li W. Chen T, et al. Fluids Barriers CNS. 2024 Jul 19;21(1):60. doi: 10.1186/s12987-024-00557-1. Fluids Barriers CNS. 2024. PMID: 39030617 Free PMC article. Review.
References
- Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet. 1997;17:263–264. - PubMed
- Best JD, Jay MT, Otu F, Ma J, Nadin A, Ellis S, Lewis HD, Pattison C, Reilly M, Harrison T, Shearman MS, Williamson TL, Atack JR. Quantitative measurement of changes in amyloid-β(40) in the rat brain and cerebrospinal fluid following treatment with the α-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide] J Pharmacol Exp Ther. 2005;313:902–908. - PubMed
- Calero M, Rostegno A, Matsubara E, Zlokovic BV, Ghiso J. Apolipoprotein J (clusterin) and Alzheimer’s disease. Micro Res Tech. 2000;50:305–315. - PubMed
- Cao D, Fukuchi K, Wan H, Kim H, Li L. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging. 2006 (in press) doi:10.1016/j.neurobiolaging.2005.09.011. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R37AG13956/AG/NIA NIH HHS/United States
- R37 NS034467/NS/NINDS NIH HHS/United States
- R37AG023084/AG/NIA NIH HHS/United States
- R37 AG023084/AG/NIA NIH HHS/United States
- NS34467/NS/NINDS NIH HHS/United States
- R01 NS034467/NS/NINDS NIH HHS/United States
- R37 AG013956/AG/NIA NIH HHS/United States
- R37 AG023084-06/AG/NIA NIH HHS/United States
- R01 NS034467-08/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous